These conclusions are based on a four-month treatment, whereas most trials go on for 18 months, and some even for 36 months. Knowing the complexity of AD pathogenesis, would a four-month treatment be considered sufficiently long to test the efficacy of an approach?

View all comments by Sanjay W. Pimplikar

I believe that the 19 percent decrease in isoprostane, however small, is very relevant because this is the first time that any antioxidant treatment in AD has been proven to engage its target. However, if oxidative stress is a culprit in AD, then antioxidant treatments, like any other disease-modifying drugs, should be tested at presymptomatic stages of the disease.

View all comments by Elena Galea